GlassScriptPhysician profile
Dana J Lukin
NPI 1760640999
$491,339.73
in general payments reported to CMS, 2019-2025
30 companies · $236K in 2025
The $236K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $4,112 · 2021: $11K · 2022: $49K · 2023: $77K · 2024: $72K · 2025: $236K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $294K · Travel and Lodging: $43K · Consulting Fee: $35K · Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $293,886.86 |
| Travel and Lodging | $43,381.31 |
| Consulting Fee | $34,846.50 |
| Food and Beverage | $12,694.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $221,906.01 | 2019-2025 | |
| Janssen Biotech, INC. | $152,993.00 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals International, INC. | $36,932.74 | 2019 | |
| Pfizer INC. | $34,901.25 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $15,278.17 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $12,463.68 | 2019-2025 | Entyvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,850.00 | 2021-2022 | |
| Janssen Global Services, LLC | $4,200.00 | 2021 | |
| Lilly USA, LLC | $2,559.90 | 2021-2025 | Zepbound, Mounjaro, Omvoh |
| Celgene Corporation | $1,918.14 | 2021-2024 | Zeposia |
| Eli Lilly and Company | $922.11 | 2022 | |
| Fresenius Kabi USA, LLC | $633.22 | 2023 | Idacio |
| Boston Scientific Corporation | $126.68 | 2022 | |
| Celltrion USA INC. | $125.23 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $55.22 | 2024-2025 | |
| Amgen INC. | $53.42 | 2023 | Amjevita, Avsola |
| Samsung Hme America, INC. | $50.00 | 2023 | |
| Madrigal Pharmaceuticals | $47.62 | 2024 | Resmetirom |
| Novo Nordisk INC | $38.97 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $32.50 | 2025 | Iqirvo |
| Janssen Scientific Affairs, LLC | $31.69 | 2024-2025 | Tremfya, Stelara |
| Braintree Laboratories, INC. | $26.08 | 2022 | |
| Evoke Pharma, INC. | $24.60 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.46 | 2024 | Xifaxan |
| Shire North American Group INC | $13.92 | 2019 | |
| Conmed Corporation | $12.12 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Lukin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.